ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents
- ENDRA's intellectual property portfolio has reached a new milestone of 70 issued patents globally, showcasing the company's innovation and commitment to protecting their thermoacoustic systems. The patents focus on areas of high unmet clinical need, such as the early detection of steatotic liver disease, indicating a strong focus on addressing critical healthcare challenges.
- None.
Global intellectual property portfolio increases to 70 issued patents
The following three patents were issued:
-
U.S. Patent No. 11806113, titled “Thermoacoustic Probe,” relates to a novel thermoacoustic probe with an optical transducer and an integrated wedge. This builds upon ENDRA’sU.S. Patent No. 11730374, which defines and protects ENDRA’s integrated wedge technology. -
Chinese Patent No. ZL 2021800299011 (the ‘011 patent), titled “Thermoacoustic Transducer with Integrated Switch,” relates to a novel system for reducing false signals in thermoacoustic imaging. ENDRA expects the ‘011 patent to be effective for all thermoacoustic imaging applications. The Chinese ‘011 patent is related to its parent patent,
U.S. Patent No. 11172829. -
Chinese Patent No. ZL 2022800094336 (the ‘336 patent), titled “Acoustically Isolated Thermoacoustic Imaging Probe and Process of Manufacture,” protects ENDRA’s proprietary manufacturing process to acoustically isolate the radiofrequency element from the transducer element. The Chinese ‘336 patent is related to its parent patent,
U.S. Patent No. US10996163.
"Our IP portfolio has reached a new milestone of 70 issued patents globally. We believe this is a remarkable achievement for a company of our size and a testament to the innovation of ENDRA," stated ENDRA's Chairman and Chief Executive Officer Francois Michelon. “These newly issued patents protect and further differentiate ENDRA's thermoacoustic systems in areas of high unmet clinical need, such as the early detection of steatotic liver disease."
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with over 700,000 ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Steatotic Liver Disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” “anticipate,” “attempt,” “believe,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,” “may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,” “will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA’s business strategy; and statements regarding ENDRA’s ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA’s business plans; the ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231108641564/en/
Company Contact:
Irina Pestrikova
Senior Director, Finance
investors@endrainc.com
www.endrainc.com
Investor Relations Contact:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com
Source: ENDRA Life Sciences Inc.
FAQ
What is the significance of ENDRA's recent patent issuance?
What do the newly issued patents focus on?
Who emphasized the significance of these patents?
What clinical need do the patents aim to address?
How many patents are included in ENDRA's intellectual property portfolio now?
